NCT06615102 (PAN-AKI) is a Phase 3 clinical trial of Angiotensin II in Cardiac Surgery, sponsored by Universität Münster.

Who is sponsoring NCT06615102?

NCT06615102 is sponsored by Universität Münster.

What drugs are being tested in NCT06615102?

Interventions in NCT06615102: Angiotensin II, Noradrenalin.

What condition does NCT06615102 study?

NCT06615102 studies Cardiac Surgery, Vasoplegia.

Is NCT06615102 still recruiting?

NCT06615102 is currently recruiting now. Last updated 15 July 2025.

Last reviewed 2025-07-15 · How we verify

NCT06615102: PAN-AKI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Prospective Angiotensin II Versus Noradrenaline Trial for Hypotension Management to Reduce Cardiac-surgery Associated Acute Kidney Injury (PAN-AKI)

Recruiting now Phase 3 Last updated 15 July 2025

What this trial tests

Phase 3 trial testing Angiotensin II in Cardiac Surgery in 1,022 participants. Currently enrolling.

Timeline

31 March 2025

Primary endpoint
1 January 2027

1 April 2027

Quick facts

Lead sponsor	Universität Münster
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	1,022
Start date	31 March 2025
Primary completion	1 January 2027
Estimated completion	1 April 2027
Sites	4 locations across Germany

Drugs / interventions tested

Angiotensin II (ANGIOTENSIN II) — full drug profile →
Noradrenalin — full drug profile →

Conditions studied

Cardiac Surgery — all drugs for Cardiac Surgery →
Vasoplegia — all drugs for Vasoplegia →

Sponsor

Universität Münster — full company profile →

Who can join

18 and older, any sex, with Cardiac Surgery or Vasoplegia. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Rate of AKI KDIGO stage 2 or 3 or death within 72 hours after end of cardiac surgery.
Time frame: 72 hours after end of surgery

Sponsor's own description

The study intervention focuses on exploring the use of angiotensin II as a primary vasopressor compared to norepinephrine in cardiac surgery patients to investigate whether angiotensin II can reduce the occurrence of moderate/severe acute kidney injury (AKI). Despite its potential, as suggested by trials involving surgical patients, there is currently no human data confirming its effectiveness in preventing moderate/severe AKI in this context. The intervention aims to address this gap by evaluating angiotensin II's impact compared to norepinephrine.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The therapeutic horizon of acute kidney injury in critical care: exploring pathology, promises, pitfalls, and progress.
Vogelaar Y, Mourisse L, Pickkers P. · · 2025 · PMID 41191836 · DOI 10.1097/mcc.0000000000001331

Verify or expand the search:

Other trials of Angiotensin II

Trials testing the same drug.

NCT06157580 — Balance of Angiotensin II Receptors in Vessel Function After Preeclampsia · EARLY_PHASE1 · completed
NCT05824767 — Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock · Phase 4 · completed
NCT04901169 — Angiotensin II in Liver Transplantation · Phase 2, PHASE3 · active not recruiting
NCT04904562 — Angiotensin II for Distributive Shock · Phase 4 · terminated
NCT05193370 — Angiotensin II vs. Vasopressin in Septic Shock · Phase 4 · withdrawn

Other recruiting trials for Cardiac Surgery

Currently open trials in the same condition.

NCT06968936 — Long-term Outcomes Sub-Study of Preoperative Combined Iron Therapy · NA · recruiting
NCT07417462 — Transversus Thoracic Muscle Plane Block Versus Pectointercostal Fascial Block for Enhanced Recovery After Cardiac Surger · NA · recruiting
NCT07193719 — Influence of Personalized Lung Volume Optimization Maneuver on Lung Function and Cardiac Performance in Children · Phase 1, PHASE2 · recruiting
NCT07116343 — Intrapleural Ropivacaine Infusion in Cardiac Surgery · Phase 4 · recruiting
NCT07354841 — Safety and Performance Evaluation of CPB Venous and Arterial Cannulas · NA · recruiting

Other Universität Münster trials

Trials by the same sponsor.

NCT07197307 — Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) · Phase 2 · not yet recruiting
NCT06912529 — Axicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma · Phase 2 · terminated
NCT06665724 — Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodyna · Phase 1 · completed
NCT06727851 — ESGE-Quality Improvement in Endoscopy: ERCP · enrolling by invitation
NCT06021288 — Standard Dose Continuous Renal Replacement Therapy (CRRT) Versus Low-Dose CRRT ( KETZEREI ) · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06615102 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Universität Münster
Last refreshed: 15 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06615102.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing